Biosimilars for rituximab, trastuzumab, and bevacizumab are currently approved for use in the European Union.
Angelica Welch
Advertisement
Articles by Angelica Welch
Cetuximab (Erbitux) with pembrolizumab (Keytruda) shows promise in patients with mCRC.
A combination VEGFR-2 inhibitor plus an anti–PD-L1 agent demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Advertisement
Latest Updated Articles
Oncology Biosimilars Bring Hope to Patients with CancerPublished: March 21st 2018 | Updated:
Combination Therapy Shows Antitumor Activity in Advanced Gastric, GEJ AdenocarcinomaPublished: January 19th 2018 | Updated:
Combo Therapy Well-Tolerate in RAS Wild-Type Metastatic Colorectal CancerPublished: January 22nd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Glucodensity Analysis Enhances CGM Accuracy for Detecting Cystic Fibrosis–Related Diabetes
4
Incidence of VAIs in Patients With Chronic Kidney Disease on Dialysis Relatively Low
5
